351
Participants
Start Date
September 30, 2011
Primary Completion Date
September 30, 2012
Study Completion Date
September 30, 2012
Fluticasone furoate 50mcg
Once daily inhalation powder via Novel Dry Powder Inhaler
Fluticasone propionate 100mcg
Twice daily inhalation powder via DISKUS/ACCUHALER
Placebo
Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
GSK Investigational Site, Utica
GSK Investigational Site, Bethesda
GSK Investigational Site, Orangeburg
GSK Investigational Site, Orlando
GSK Investigational Site, Hialeah
GSK Investigational Site, Aventura
GSK Investigational Site, Clearwater
GSK Investigational Site, Guadalajara
GSK Investigational Site, Zapopan
GSK Investigational Site, Cincinnati
GSK Investigational Site, Columbia
GSK Investigational Site, Metairie
GSK Investigational Site, Sunset
GSK Investigational Site, Corsicana
GSK Investigational Site, Waco
GSK Investigational Site, El Paso
GSK Investigational Site, Las Vegas
GSK Investigational Site, Los Angeles
GSK Investigational Site, Rolling Hills Estates
GSK Investigational Site, San Jose
GSK Investigational Site, Sacramento
GSK Investigational Site, Moscow
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Novosibirsk
GSK Investigational Site, Kemerovo
GSK Investigational Site, Brick
GSK Investigational Site, Mexico City
GSK Investigational Site, Almelo
GSK Investigational Site, Eindhoven
GSK Investigational Site, Eindhoven
GSK Investigational Site, Hoogwoud
GSK Investigational Site, Zutphen
GSK Investigational Site, Lima
GSK Investigational Site, Lima
GSK Investigational Site, San Miguel
GSK Investigational Site, Lima
GSK Investigational Site, Bydgoszcz
GSK Investigational Site, Krakow
GSK Investigational Site, Lodz
GSK Investigational Site, Lublin
GSK Investigational Site, Poznan
GSK Investigational Site, Wroclaw
Lead Sponsor
GlaxoSmithKline
INDUSTRY